Key statistics
As of last trade, Elicio Therapeutics Inc (9HA:FRA) traded at 4.60, 53.33% above the 52 week low of 3.00 set on Jan 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.60 |
---|---|
High | 4.60 |
Low | 4.60 |
Bid | 4.66 |
Offer | 4.90 |
Previous close | 4.18 |
Average volume | 0.00 |
---|---|
Shares outstanding | 10.77m |
Free float | 7.96m |
P/E (TTM) | -- |
Market cap | 54.73m USD |
EPS (TTM) | -4.83 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 08:59 GMT.
More ▼
Announcements
- Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
- Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
- Elicio Therapeutics Reports Inducement Grants
- Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
- Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
- Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
- Elicio Therapeutics Announces Proposed Public Offering
- Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
More ▼